Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$2.42M-$2.42MN/M vs Q3 2022 EPS Diluted-$1.77-$1.77N/M vs Q3 2022 Operating Income-$3,122,000N/M Operating Cash Flowderived-$1,964,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 1, 2023 · 32 d after period end